MedTrace Logo

Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.

NCT02957760 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-11-28

No results posted yet for this study

Summary

The central retinal vein occlusion (CRVO) is a major cause of ocular morbidity, depending in particular on the occurrence and extent of retinal ischemia by capillary occlusion. There is no effective systemic treatment of this condition. An increase in the adhesion of erythrocytes to vascular endothelium was observed for patients with CRVO, correlated with overexpression of membrane phosphatidylserine

Conditions

  • Central Retinal Vein Occlusion, Non-Ischemic

Interventions

DRUG

Hydroxycarbamid

20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).

Sponsors & Collaborators

  • Hopital Universitaire Robert-Debre

    collaborator OTHER

  • Institut National de la Transfusion Sanguine

    collaborator OTHER

  • Keyrus Biopharma

    collaborator OTHER

  • For Drug Consulting

    collaborator OTHER

  • Theravia

    collaborator INDUSTRY

  • Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

    lead OTHER

Principal Investigators

  • Jean-François Girmens · CHNO des Quinze-Vingts

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-08-31
Completion
2017-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02957760 on ClinicalTrials.gov